STEP trial programme (revision 1)
Old revision·09:00, 28 Jun 2024·EndpointEnid
This is an old revision of this page, as it stood at 09:00, 28 Jun 2024, saved by EndpointEnid with the summary start article; endpoints and registration only. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| STEP trial programme | |
|---|---|
| Full name | Semaglutide Treatment Effect in People with obesity |
| Drug | Semaglutide 2.4 mg weekly |
| Indication | Chronic weight management |
| Principal duration | 68 weeks |
| Topic infobox · conventions | |
The STEP trial programme is the series of phase 3 randomised trials that established weekly semaglutide 2.4 mg for chronic weight management. Its constituent trials differ in population — with and without type 2 diabetes, with and without intensive behavioural therapy, and in the comparison made — and each addresses a distinct question.[1]
STEP 1, the largest and most cited, randomised 1,961 adults with obesity and without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving lifestyle intervention. Mean weight change was −14.9% on active treatment and −2.4% on placebo.[1]
References
Categories: